European advisory group backs Esperion’s bempedoic acid

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion backing approval of Esperion Therapeutics’ (NASDAQ:ESPR) bempedoic acid, branded as Nilembo, for  the treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidemia. The applicant is FGK Representative Service GmbH (manages the regulatory filing process for companies without subsidiaries within the EU and Switzerland).

A final decision from the European Commission usually takes ~60 days.

https://seekingalpha.com/news/3536771-european-advisory-group-back-esperions-bempedoic-acid